EMA accepts application for ranibizumab biosimilar from Samsung Bioepis

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

EMA accepts application for ranibizumab biosimilar from Samsung Bioepis

Biosimilars/News | Posted 23/10/2020 0 Post your comment

Korea-based Samsung Bioepis (Samsung and Biogen’s joint venture) announced on 6 October 2020 that the European Medicines Agency (EMA) has accepted to review its marketing authorization application for SB11, a biosimilar of Lucentis® (ranibizumab). If successful, this will be the first Lucentis® biosimilar available in Europe.

Ranibizumab is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. Ranibizumab inhibits angiogenesis (the formation of new blood vessels) by inhibiting vascular endothelial growth factor A (VEGF-A), a mechanism similar to bevacizumab [1].

Ranibizumab [2] is an eye disease treatment, specifically for retinal vascular disorders, which are a leading cause of blindness. Ranibizumab can be used to treat macular degeneration by inhibiting VEGF, which is responsible for the excessive formation of blood vessels in the retina leading to progressive loss of vision. The monoclonal antibody drug is indicated for the treatment of wet age-related macular degeneration (AMD), macular oedema, degenerative myopia and diabetes complications; all conditions of the eye causing vision loss.

Samsung Bioepis and Biogen are collaborating to create SB11, a more affordable potential treatment option for patients with retinal vascular disorders. Through this, and the development of other biosimilars, they hope to facilitate healthcare sustainability and improve patient access to drugs and treatment globally.

The collaboration between the two companies sees biosimilar development by Samsung Bioepis and commercialization by Biogen. This commercialization agreement was announced in November 2019 [3] and surrounds the development and commercialization of two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in Australia, Canada, Europe, Japan and the US.

Samsung Bioepis releases data on trastuzumab and ranibizumab biosimilars

Advances in ranibizumab and teriparatide biosimilars

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 23]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of ranibizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 23]. Available from:
www.gabionline.net/Biosimilars/General/Biosimilars-of-ranibizumab
3. GaBI Online - Generics and Biosimilars Initiative. Samsung Bioepis expands biosimilars agreement with Biogen [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 23]. Available from: www.gabionline.net/Pharma-News/Samsung-Bioepis-expands-biosimilars-agreement-with-Biogen

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.